Department of Thoracic and Cardiovascular Surgery, Dongsan Medical Center, Keimyung University College of Medicine, Daegu 700-712, Korea.
Korean J Radiol. 2012 Jul-Aug;13(4):476-82. doi: 10.3348/kjr.2012.13.4.476. Epub 2012 Jun 18.
This study aimed to assess the surgical morbidity and mortality of thoracic endovascular repair (TEVAR) as compared with open surgical repair (OSR) for isolated descending thoracic aortic disease.
From January 1, 2006 through May 31, 2010, a total of 68 patients with isolated descending thoracic aortic disease were retrospectively reviewed for the presence of perioperative complication, 30-day mortality, and clinical success. The patients were divided into two groups (group 1, OSR, n = 40 vs. group 2, TEVAR, n = 28) and these groups were compared for major variables and late outcomes.
The mean age was 58 years (group I = 54 vs. group II = 63 years, p = 0.011). Significant perioperative complications occurred in 12 patients: 8 (20%) in group I and 4 (13%) in group II (p = 0.3). There were five 30 day mortalities of which 4 occurred in group I and 1 in group II (p = 0.23). Clinical success (effective aortic remodeling and complete false lumen obliteration or thrombosis) was achieved in 20 patients (71%). Mean Kaplan-Meier survival rate at 1 year was similar for both groups (group 1 = 87% vs. group 2 = 80%, p = 0.65).
Thoracic endovascular repair for isolated thoracic aortic disease shows comparable results to OSR. However, the potential for endoleak or rupture remains a challenge that needs to be addressed in the future. Therefore, close follow-up study is needed for the evaluation of satisfactory long-term outcomes.
本研究旨在评估胸主动脉腔内修复术(TEVAR)与开放手术修复(OSR)治疗孤立性胸降主动脉疾病的手术发病率和死亡率。
从 2006 年 1 月 1 日至 2010 年 5 月 31 日,回顾性分析了 68 例孤立性胸降主动脉疾病患者的围手术期并发症、30 天死亡率和临床疗效。将患者分为两组(组 1,OSR,n=40 例;组 2,TEVAR,n=28 例),比较两组主要变量和晚期结果。
平均年龄为 58 岁(组 1=54 岁,组 2=63 岁,p=0.011)。12 例患者发生严重围手术期并发症:组 1 8 例(20%),组 2 4 例(13%)(p=0.3)。30 天内死亡 5 例,组 1 4 例,组 2 1 例(p=0.23)。20 例(71%)患者临床疗效(主动脉有效重塑和完全假腔闭塞或血栓形成)。两组 1 年Kaplan-Meier 生存率相似(组 1=87%,组 2=80%,p=0.65)。
TEVAR 治疗孤立性胸主动脉疾病的结果与 OSR 相当。然而,内漏或破裂的潜在风险仍然是一个挑战,需要在未来加以解决。因此,需要进行密切的随访研究,以评估满意的长期疗效。